Skip to content

Price / book at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
2.7×-7.2×
LQD
Liquidia CorporationLQDA
30.6×+5.3×
Royalty Pharma logo
Royalty PharmaRPRX
2.1×+0.7×
United Therapeutics logo
United TherapeuticsUTHR
4.4×+2.4×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
3.5×+0.3×
Precigen logo
PrecigenPGEN
67.7×

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$890.32M+67.5%
Enterprise value$642.72M+37.0%
P/E7.8×
P/S8.1×0.0×

Profitability

See full
Gross margin60.8%
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Calculated from Theravance Biopharma’s reported figures.

Based on the most recent quarter.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Theravance Biopharma's price / book?
Theravance Biopharma (TBPH) reported price / book of 2.9× in Q1 2026.
How has Theravance Biopharma's price / book changed year-over-year?
Theravance Biopharma's price / book increased by 8.1% year-over-year, from 2.7× to 2.9×.
What is the long-term trend for Theravance Biopharma's price / book?
Over 3 years (2022 to 2025), Theravance Biopharma's price / book has grown at a 23.1% compound annual growth rate (CAGR), from 1.7× to 3.2×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.